Study
EORTC-90101
Cross-tumoral Phase 2 clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET ("CREATE")
Trial Status
LT-FU ongoing
Dates
Date of activation: 27-Aug-2012
Date Step1 close: 04-Jul-2017
Date Step2 close: 04-Jul-2017
Date Step1 close: 04-Jul-2017
Date Step2 close: 04-Jul-2017
Data management at EORTC
Yes
Design
Phase 2
Randomized open label
Randomized open label
Targeted Sample size
EORTC Groups: 582 - All Groups: 582
Treatment
Drug
Crizotinib
Crizotinib
Study Staff
- Patrick Schoeffski (Study Coordinator), U.Z. Leuven - Campus Gasthuisberg, Leuven
- Lieve Dirix (Senior Clinical Operations Manager), EORTC Headquarters, Brussels
- Leslie Herman (Regulatory Affairs Manager), EORTC Headquarters, Brussels
- Sandrine Marreaud (Clinical Research Physician), EORTC Headquarters, Brussels
- Sara Meloen (Pharmacovigilance Manager), EORTC Headquarters, Brussels
- Axelle Nzokirantevye (Data Manager), EORTC Headquarters, Brussels
- Xiao Mang Zhou (Regulatory Affairs Manager), EORTC Headquarters, Brussels
Type of cancer
- Non Hodgkins Lymphoma
- Kidney
- Soft Tissue and Bone Sarcoma
Recruiting centers
- Centre Georges-Francois-Leclerc (DIJON CEDEX, France)
- Centre Leon Berard (Lyon, France)
- Gustave Roussy (VILLEJUIF CEDEX, France)
- Helios Klinikum Bad Saarow (Bad Saarow-Pieskow, Germany)
- Hopital de La Timone (APHM) (MARSEILLE, France)
- IRCCS - Fondazione Istituto Nazionale dei Tumori (Milano, Italy)
- Institut Bergonie (Bordeaux, France)
- Institut Jules Bordet (Anderlecht, Belgium)
- Leeds Teaching Hospitals NHS Trust - St. James's University Hospital (Leeds, United Kingdom)
- Leiden University Medical Centre (Leiden, Netherlands)
- Ludwig-Maximilians-Universitaet Muenchen - Campus Grosshadern (Muenchen, Germany)
- Maria Sklodowska-Curie National Research Institute of Oncology (Warsaw, Poland)
- Medizinische Hochschule Hannover (Hannover, Germany)
- Narodny Onkologicky Ustav - Bratislava (Bratislava, Slovakia)
- Nottingham University Hospitals NHS Trust - City Hospital (Nottingham, United Kingdom)
- Oslo University Hospital - Radiumhospitalet (Oslo, Norway)
- Radboud University Medical Center Nijmegen (Nijmegen, Netherlands)
- The Christie NHS Foundation Trust (Manchester, United Kingdom)
- The Institute Of Oncology (Ljubljana, Slovenia)
- U.Z. Leuven - Campus Gasthuisberg (Leuven, Belgium)
- UniversitaetsMedizin Mannheim (Mannheim, Germany)
- Universitaetsklinikum - Essen (Essen, Germany)
- Universitaetsklinikum Carl Gustav Carus (TUD) (Dresden, Germany)
- University College Hospital (London, United Kingdom)
Protocol summary
NCT number
NCT01524926